{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:00:19Z","timestamp":1794344419318,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016670","name":"Region \u00d6sterg\u00f6tland","doi-asserted-by":"crossref","award":["ALF Grants"],"award-info":[{"award-number":["ALF Grants"]}],"id":[{"id":"10.13039\/100016670","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008799","name":"Gilead Foundation","doi-asserted-by":"publisher","award":["Non-restricted Grant"],"award-info":[{"award-number":["Non-restricted Grant"]}],"id":[{"id":"10.13039\/100008799","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diapharma","award":["Non-restricted Grant"],"award-info":[{"award-number":["Non-restricted Grant"]}]},{"name":"Faculty of Medicine, Link\u00f6ping University","award":["Lion Research Grant"],"award-info":[{"award-number":["Lion Research Grant"]}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["VR 2020-04826"],"award-info":[{"award-number":["VR 2020-04826"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) affects 20\u201330% of the general adult population. NAFLD patients with type 2 diabetes mellitus (T2DM) are at an increased risk of advanced fibrosis, which puts them at risk of cardiovascular complications, hepatocellular carcinoma, or liver failure. Liver biopsy is the gold standard for assessing hepatic fibrosis. However, its utility is inherently limited. Consequently, the prevalence and characteristics of T2DM patients with advanced fibrosis are unknown. Therefore, the purpose of the current study is to evaluate the prevalence and severity of NAFLD in patients with T2DM by recruiting participants from primary care, using the latest imaging modalities, to collect a cohort of well phenotyped patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We will prospectively recruit 400 patients with T2DM using biomarkers to assess their status. Specifically, we will evaluate liver fat content using magnetic resonance imaging (MRI); hepatic fibrosis using MR elastography and vibration-controlled transient elastography; muscle composition and body fat distribution using water-fat separated whole body MRI; and cardiac function, structure, and tissue characteristics, using cardiovascular MRI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>We expect that the study will uncover potential mechanisms of advanced hepatic fibrosis in NAFLD and T2DM and equip the clinician with better diagnostic tools for the care of T2DM patients with NAFLD.<\/jats:p><jats:p><jats:italic>Trial registration:<\/jats:italic>Clinicaltrials.gov, identifier NCT03864510. Registered 6 March 2019,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03864510\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03864510<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-021-01763-z","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T11:09:37Z","timestamp":1618916977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol"],"prefix":"10.1186","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct03864510","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-4188","authenticated-orcid":false,"given":"Patrik","family":"Nasr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-7565","authenticated-orcid":false,"given":"Fredrik","family":"Iredahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-0913","authenticated-orcid":false,"given":"Karin","family":"R\u00e5dholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-7048","authenticated-orcid":false,"given":"Pontus","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Cedersund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Dahlqvist Leinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-8296","authenticated-orcid":false,"given":"Tino","family":"Ebbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Alfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-9690","authenticated-orcid":false,"given":"Carl-Johan","family":"Carlh\u00e4ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2232","authenticated-orcid":false,"given":"Peter","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7614-739X","authenticated-orcid":false,"given":"Stergios","family":"Kechagias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5590-8601","authenticated-orcid":false,"given":"Mattias","family":"Ekstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"1763_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"1763_CR2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063\u201372.","journal-title":"N Engl J Med"},{"key":"1763_CR3","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.23527","volume":"51","author":"MS Ascha","year":"2010","unstructured":"Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972\u20138.","journal-title":"Hepatology"},{"key":"1763_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","volume":"65","author":"R Pais","year":"2016","unstructured":"Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, et al. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245\u201357.","journal-title":"J Hepatol"},{"key":"1763_CR5","doi-asserted-by":"crossref","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 2017; Accepted article.","DOI":"10.1016\/j.jhep.2017.07.027"},{"issue":"1611\u20131625","key":"1763_CR6","first-page":"e1612","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstr\u00f6m H, Nasr P, Schattenberg JM, Ishigami M, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(1611\u20131625):e1612.","journal-title":"Gastroenterology"},{"issue":"389\u2013397","key":"1763_CR7","first-page":"e310","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(389\u2013397):e310.","journal-title":"Gastroenterology"},{"key":"1763_CR8","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","volume":"58","author":"M Stepanova","year":"2013","unstructured":"Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017\u201323.","journal-title":"Dig Dis Sci"},{"key":"1763_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u201354.","journal-title":"Hepatology"},{"key":"1763_CR10","doi-asserted-by":"crossref","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017.","DOI":"10.1002\/hep.29085"},{"key":"1763_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"N Cho","year":"2018","unstructured":"Cho N, Shaw J, Karuranga S, Huang Y, da Rocha FJ, Ohlrogge A, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271\u201381.","journal-title":"Diabetes Res Clin Pract"},{"key":"1763_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1763_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1763_CR14","doi-asserted-by":"crossref","unstructured":"Nasr P, Fredrikson M, Ekstedt M, Kechagias S. The amount of liver fat predicts mortality and development of type 2 diabetes in non\u2010alcoholic fatty liver disease. Liv. Int. 2020.","DOI":"10.1111\/liv.14414"},{"key":"1763_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0168-8278(86)80075-7","volume":"2","author":"F Piccinino","year":"1986","unstructured":"Piccinino F, Sagnelli E, Pasquale G, Giusti G, Battocchia A, Bernardi M, Bertolazzi R, et al. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68 276 biopsies. J Hepatol. 1986;2:165\u201373.","journal-title":"J Hepatol"},{"key":"1763_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cgh.2008.12.015","volume":"7","author":"R Vuppalanchi","year":"2009","unstructured":"Vuppalanchi R, \u00dcnalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, Tonascia J, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:481\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1763_CR17","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898\u2013906.","journal-title":"Gastroenterology"},{"key":"1763_CR18","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"1763_CR19","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005\u201323.","journal-title":"Hepatology"},{"key":"1763_CR20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","volume":"65","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65:1006\u201316.","journal-title":"J Hepatol"},{"issue":"53\u201355","key":"1763_CR21","first-page":"e57","volume":"153","author":"P Nasr","year":"2017","unstructured":"Nasr P, Forsgren MF, Ignatova S, Dahlstr\u00f6m N, Cedersund G, Leinhard OD, Nor\u00e9n B, et al. Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of hepatic steatosis, based on results from histopathology analysis. Gastroenterology. 2017;153(53\u201355):e57.","journal-title":"Gastroenterology"},{"key":"1763_CR22","unstructured":"(EMA) EMA. ICH E6 (R2) Good clinical practice. In. https:\/\/www.ema.europa.eu\/en\/ich-e6-r2-good-clinical-practice; 2016."},{"key":"1763_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/apt.13405","volume":"43","author":"I Doycheva","year":"2016","unstructured":"Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"1763_CR24","doi-asserted-by":"crossref","unstructured":"Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998;158:1789\u20131795.","DOI":"10.1001\/archinte.158.16.1789"},{"key":"1763_CR25","doi-asserted-by":"crossref","unstructured":"Skinner HA, Sheu W-J. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J. Stud. Alcohol 1982;43:1157\u20131170.","DOI":"10.15288\/jsa.1982.43.1157"},{"key":"1763_CR26","unstructured":"Socialstyrelsen. Utdrag ur indikatorbilagan f\u00f6r Nationella riktlinjer f\u00f6r sjukdomsf\u00f6rebyggande metoder 2011. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2020-2-6596.pdf; 2020."},{"key":"1763_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/1403494815602830","volume":"44","author":"SJ Olsson","year":"2016","unstructured":"Olsson SJ, Ekblom \u00d6, Andersson E, B\u00f6rjesson M, Kallings LV. Categorical answer modes provide superior validity to open answers when asking for level of physical activity: a cross-sectional study. Scand J Public Health. 2016;44:70\u20136.","journal-title":"Scand J Public Health"},{"key":"1763_CR28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/ije\/dyr039","volume":"40","author":"FB Ortega","year":"2011","unstructured":"Ortega FB, Ruiz JR, Espa\u00f1a-Romero V, Vicente-Rodriguez G, Mart\u00ednez-G\u00f3mez D, Manios Y, B\u00e9ghin L, et al. The International Fitness Scale (IFIS): usefulness of self-reported fitness in youth. Int J Epidemiol. 2011;40:701\u201311.","journal-title":"Int J Epidemiol"},{"key":"1763_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540\u20135.","journal-title":"Sleep"},{"key":"1763_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193\u2013213.","journal-title":"Psychiatry Res"},{"key":"1763_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/ALN.0b013e31816d83e4","volume":"108","author":"F Chung","year":"2008","unstructured":"Chung F, Yegneswaran B, Liao P, Sharon, Vairavanathan S, Islam S, Khajehdehi A, et al. STOP questionnaire. Anesthesiology. 2008;108:812\u201321.","journal-title":"Anesthesiology"},{"key":"1763_CR32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"1763_CR33","doi-asserted-by":"crossref","unstructured":"ATS Statement. Am J Respir Crit Care Med. 2002;166:111\u20137.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"1763_CR34","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, Beaugrand M, De Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, et al. Controlled Attenuation Parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825\u201335.","journal-title":"Ultrasound Med Biol"},{"key":"1763_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"1763_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547\u201355.","journal-title":"Gastroenterology"},{"issue":"748\u2013755","key":"1763_CR37","first-page":"e743","volume":"17","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(748\u2013755):e743.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1090\u20131099","key":"1763_CR38","first-page":"e1091","volume":"152","author":"D Goldberg","year":"2017","unstructured":"Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152(1090\u20131099):e1091.","journal-title":"Gastroenterology"},{"key":"1763_CR39","doi-asserted-by":"publisher","first-page":"154183","DOI":"10.1016\/j.metabol.2020.154183","volume":"2010","author":"S Kechagias","year":"2020","unstructured":"Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020;2010:154183.","journal-title":"Metabolism"},{"key":"1763_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hep4.1134","volume":"2","author":"P Nasr","year":"2018","unstructured":"Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2:199\u2013210.","journal-title":"Hepatol Commun"},{"key":"1763_CR41","unstructured":"Collaboration NCDRF. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017;390:2627\u201342."},{"key":"1763_CR42","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/obr.12407","volume":"17","author":"L Li","year":"2016","unstructured":"Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17:510\u20139.","journal-title":"Obes Rev"},{"key":"1763_CR43","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686\u201390.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1763_CR44","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.2174\/1381612826666200310142803","volume":"26","author":"P Nasr","year":"2020","unstructured":"Nasr P, Blomdahl J, Kechagias S, Ekstedt M. Modifiers of liver-related manifestation in the course of NAFLD. Curr Pharm Des. 2020;26:1062\u201378.","journal-title":"Curr Pharm Des"},{"key":"1763_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"M Thursz","year":"2018","unstructured":"Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, Spahr L, Sterneck M, et al. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154\u201381.","journal-title":"J Hepatol"},{"key":"1763_CR46","doi-asserted-by":"crossref","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020:gutjnl-2020\u20132320.","DOI":"10.1136\/gutjnl-2020-320622"},{"key":"1763_CR47","doi-asserted-by":"crossref","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Askling J, Hultcrantz R, et al. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver International 2018.","DOI":"10.1111\/liv.13973"},{"key":"1763_CR48","doi-asserted-by":"crossref","unstructured":"Cassidy S, Hallsworth K, Thoma C, Macgowan GA, Hollingsworth KG, Day CP, Taylor R, et al. Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control. 2015;14:23.","DOI":"10.1186\/s12933-015-0187-2"},{"key":"1763_CR49","doi-asserted-by":"crossref","unstructured":"Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L, Slomko J, et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J. Hepatol. 2019.","DOI":"10.1016\/j.jhep.2019.01.035"},{"key":"1763_CR50","doi-asserted-by":"publisher","first-page":"33386","DOI":"10.1038\/srep33386","volume":"6","author":"S Wu","year":"2016","unstructured":"Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6:33386.","journal-title":"Sci Rep"},{"key":"1763_CR51","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","volume":"33","author":"LS Bhatia","year":"2012","unstructured":"Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33:1190\u2013200.","journal-title":"Eur Heart J"},{"key":"1763_CR52","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/hep.28253","volume":"63","author":"VW Wong","year":"2016","unstructured":"Wong VW, Wong GL, Yeung JC, Fung CY, Chan JK, Chang ZH, Kwan CT, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology. 2016;63:754\u201363.","journal-title":"Hepatology"},{"key":"1763_CR53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2016.01.016","volume":"246","author":"AL Fracanzani","year":"2016","unstructured":"Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata D, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis. 2016;246:208\u201313.","journal-title":"Atherosclerosis"},{"key":"1763_CR54","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/oby.22210","volume":"26","author":"J Linge","year":"2018","unstructured":"Linge J, Borga M, West J, Tuthill T, Miller MR, Dumitriu A, Thomas EL, et al. Body composition profiling in the UK Biobank Imaging Study. Obesity. 2018;26:1785\u201395.","journal-title":"Obesity"},{"key":"1763_CR55","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jcmg.2016.10.024","volume":"10","author":"RV Shah","year":"2017","unstructured":"Shah RV, Anderson A, Ding J, Budoff M, Rider O, Petersen SE, Jensen MK, et al. Pericardial, but not hepatic, fat by CT is associated with CV outcomes and structure: the multi-ethnic study of atherosclerosis. JACC Cardiovasc Imaging. 2017;10:1016\u201327.","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01763-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T20:40:42Z","timestamp":1671914442000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01763-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01763-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All recruitment and attained written informed consent are conducted according to World Medical Association of Helsinki 2018. Data is collected in accordance with the applicable General Data Protection Regulation (EU) 2016\/679 (GDPR) legislation, and in compliance with the International Conference of Harmonization\u2014Good Clinical Practice (ICH-GCP) requirements []. The EPSONIP study was approved by the Regional Ethical Board 2018\/176-31 and 2018\/494-32 and is registered as a clinical trial (clinicaltrials.gov identifier NCT 03864510). A complementary amendment, titled EPSONIP\u2014Sleep, has been approved by the Swedish Ethical Review Authority 2019-03854.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}